The cytokine interleukin-l[3 may have an important role in the autoimmune mediated damage of pancreatic Beta cells in insulin-dependent diabetes mellitus. In the present study we have investigated the effects of an interleukin-1 receptor antagonist protein, a blocker of the type I interleukin-1 receptor, on the suppressive actions of recombinant interleukin-1 [3 on insulin-producing cells. Brief exposure (1-2 h) of rat and mouse pancreatic islets to 10 ng/ml recombinant interleukin-l[3 induced an 70-80% inhibition of insulin response to glucose after 12 h. These effects were completely counteracted by co-incubation with 100 ng/ml interleukin-1 receptor antagonist protein. When rat islets were cultured for 48 h in the presence of recombinant interleukin-l[~ (5 ng/ml) higher concentrations of interleukin-1 receptor antagonist protein (5000 ng/ml) were required to protect Beta-cell function. Interleukin-1 receptor antagonist protein also counteracted the inhibitory effects of recombinant interleukin-l[3 on the growth of the rat insulinoma cell line RINm5E These data suggest that interleukin-1 receptor antagonist protein can protect insulin-producing cells from the deleterious effects of recombinant interleukin-113, and that these cells possess type I interleukin-1 receptors.
The clinical outbreak of insulin-dependent diabetes mellitus is preceded by a chronic autoimmune assault to the pancreatic Beta cells. It has been suggested that the cytokine interleukin-1 (IL-1) may be one of the main mediators of this autoimmune reaction [1] . Long-term in vitro exposure of rodent pancreatic islets, or insulinoma cell lines, to recombinant IL-I[~ (rIL-l[3) suppresses insulin production and release, and can lead to Beta-cell death [1-31 . Although the ultimate mechanism of action of rIL-113 on insulin-producing cells remains to be clarified, recent data suggest that the cytokine binds to specific surface receptors [4] . This is followed by activation of gene transcription and protein translation [5, 6] and, in the case of rat islets, progressive impairment of mitochondrial function or, in the case of mouse islets, decreased insulin mRNA and consequent decrease in proinsulin biosynthesis and insulin release [2] .
The complexity of the putative molecular mechanism of action of IL-I~ in the Beta-cells makes it difficult to envisage a way to protect these cells from the deleterious effects of IL-1. Probably the most feasible approach would be to block the binding of the cytokine to the Beta-cell receptors. Recently, an interleukin-1 receptor antagonist protein (IRAP) has been purified, cloned and expressed in Escherichia coli [7] . IRAP blocks the type 1 IL-1 receptor, found on T cells and fibroblasts. In the present study we investigated the effects of IRAP on the rIL-l[3 actions on rat and mouse pancreatic islets, and on the rat insulinoma cell line RINm5E We demonstrated that IRAP can protect these different insulin-producing cells from the suppressive effects of rIL-l[3. These data suggest that the Beta-cells possess type i IL-1 receptors, and open the possibility for in vivo tests of this compound in rodent models of spontaneous insulin-dependent diabetes mellitus.
Materials and methods

Materials
Human recombinant IL-113 (rIL-1[3) was kindly provided by Dr. S. Gillis (Immunex, Seattle, Wash., USA). The biological activity of rIL-l[3 was 5 U/ng, as compared with an interim international standard rIL-113 preparation (NIBSC, London, UK). The concentra- 
Results and discussion
One hour exposure of rat pancreatic islets to 10 ng/ml rIL-lJ3 induced a 80% decrease in glucose-stimulated (16.7 mmol/1) insulin release 12 h after exposure to the cytokine ( Fig. 1 a) . These data are in good agreement with recent observations by us [6] and others [5] , suggesting that a brief exposure of rat [5, 6, present data] and mouse islets (present data, see below) to rIL-l[3 is sufficient to induce a long period of Beta-cell functional suppression. The presence of 10 ng/ml IRAP did not modify the suppressive effects of rIL-lf~, but IRAP concentrations in the range of 100 to 10 000 ng/ml were able to completely block the effects of rIL-1[3 (p < 0.001 as compared to islets exposed to rIL-1 [3) . IRAP alone did not modify islet function. In these and the experiments described below (Figs. i a, 1 b and Table 1 ) there were no differences in the basal insulin secretion at 1.7 mmol/1 glucose among the various control and experimental groups. The pooled values at 1.7 mmol/1 glucose of the control islets, cultured in the absence of rIL-l[3 or IRAR was 4.7+0.8ng/10 islets x 60 rain (n = 23). In a second series of experiments islets were exposed for 2h to rlL-l[3, and IRAP
Methods
Pancreatic islets were isolated by collagenase digestion from adult male Sprague-Dawley rats bred in a local colony (Biomedical Centre, Uppsala, Sweden) or from adult mate NMRI mice (Anticimex, Sollentuna, Sweden) [2, 6] . The rat insulinoma cell line RINm5F was originally obtained from Dr. A_ Lernmark, Copenhagen, Denmark, seven years ago. The rat and mouse islets were cultured free-floating in medium RPMI 1640 containing 11.1 mmol/1 glucose and supplemented with 10% (volume/volume) of donor calf serum [2] . Growing RINm5F cells were trypsinized and subcultured in RPMI 1640 supplemented with 10% (volume/volume) fetal calf serum, as previously described [3] . Exposure of rat and mouse islets to rIL-l[3 was performed for 60-120 rain in culture medium, as described above. Unless indicated, IRAP was always added 15-20 min before rIL-l[3. After exposure to rIL-l[3 and/or IRAR the islets were washed in RPMI 1640, transferred to new culture dishes and maintained in culture medium for 12 h without any further additions before being functionally studied. In some experiments, rat islets or RINm5F cells were cultured for 48 h in the presence of both rIL-113 and IRAP before functional studies.
Insulin release, insulin accumulation in the medium, islet DNA and insulin content were determined as previously described [2, 6] . Briefly, insulin release was studied in triplicate groups of 10 islets by a first hour incubation at 1.7 mmol/1 glucose. The incubation medium, Krebs-Ringer bicarbonate buffer supplemented with 2 mg/ml bovine serum albumin and 10 mmol/1 Hepes, was then gently removed and replaced by medium containing 16.7 mmol/t glucose and the incubation continued for a second 60 min period. For the determination of RINm5F cell growth, i gCi/ml 3H-thymidine was added to the culture medium during the last i h of a 48 h culture in the presence of rIL-l[3 and IRAR and thymidine incorporation measured as previously described [3] .
Statistical analysis
Data were analysed by analysis of variance (ANOVA). (1000 ng/ml) was added to the medium only during the second hour (Fig. lb) . After 12 h, rIL-l[3 induced a similar 80% decrease in insulin release, as observed in Figure i a, and this effect was not significantly influenced by IRAR These findings suggest that IRAP inhibit rIL-1[3 actions on Beta-cells by blocking surface receptor binding, and will be unable to counteract the effects of the cytokine once the initial binding and putative generation of intracellular signals have occurred.
In the short-and long-term experiments (see below) using rat islets there were no differences in DNA or insulin content among the different control and experimental groups. The pooled DNA and insulin content values for the control islets were 319 + 18 ng DNA/10 islets and 751 + 53 ng insulin/10 islets (n = 23).
To evaluate the protective effects of IRAP against riLl[3 under long-term culture conditions, rat islets were cultured in the presence of rlL-l[3 (5 ng/ml) and IRAP for 48 h. Culture in the presence of high concentrations of IRAP did not affect islet function, as evaluated by insulin accumulation in the medium and the acute islet glucosestimulated insulin release (Table 1) . rIL-l[3 inhibited both parameters by 75-90%, and this effect was not counteracted by 500 ng/ml IRAR By increasing the IRAP concentration to 5000 ng/ml a partial protection against the inhibitory effects of rIL-l[3 was observed (p <0.05 vs controls and p < 0.001 vs rIL-l [3) . In order to test if this relative lack of protection by IRAP over a 48 h period in culture was related to IRAP degradation, a new series of experiments was performed. Hence, rat islets were exposed to rIL-l[3 (5 ng/ml) and IRAP (500 ng/ml) for 48 h and the medium changed every 12 h with the addition of fresh IRAP and rIL-l[3. Under these conditions rIL-l[3 again suppressed acute glucose-induced (16.7 mmol/ml) insulin release after 48 h. The control islets released 46 + 4 ng insulin/10 islets x 60 min and the rIL-l[3-treated islets 4 + 1 ng insulin/10 islets x 60 min (n = 4,p < 0.001 vs controls). IRAP completely counteracted the inhibitory action of rIL-l[3 on insulin release (IRAP+rIL-I[3-treated islets; 42 + 5 ng insulin/10 islets • 60 min, n = 4, p > 0.2 vs controls). Interestingly, when fresh rIL-l[3 was added every 12 h it induced a decrease in both islet DNA content (controls; 296 + 12 ng DNA/10 islets and rIL-lJ3-treated islets; 203 + 19 ng DNA/10 islets, n = 4, p < 0.01) and islet insulin content (controls; 528 + 63 ng insulin/10 islets and rIL-l[3-treated islets; 348 +77 ng insulin/10 islets, n = 4, p < 0.02). IRAP was again able to block these deleterious effects of rIL-l[3 (IRAP + rIL-l[3-treated islets; 261 + 16 ng DNA/10 islets and 441 + 32 ng insulin/10 islets, n = 4, p > 0.05 vs controls). Islet culture in the presence of IRAP alone did not affect islet function, insulin or DNA content (data not shown). These observations suggest that when fresh IRAP is added every 12 h it can protect the pancreatic islets from an rIL-l[3 induced decrease in insulin release, DNA and insulin content over long periods in culture. It has been shown that IRAP is stable for up to 7 days at 37~ in the presence of RPMI 1640 plus 5-10% calf serum (Tracey et al., unpublished data). The present data nevertheless suggest that IRAP may not be stable under culture conditions in the presence of pancreatic islets.
447
A brief (2 h) exposure of mouse pancreatic islets to rILd[3 (10 ng/ml) induced a similar suppression of glucose-induced (16.7 mmol/1) release after 12 h as observed in the rat islets. The control islets released 52 + 3 ng insulin/10 islets• and the rIL-l[3-treated islets 16 _+ 5 ng insulin/10 islets x 60 rain (n = 4,p < 0.05). IRAP (500 ng/ml) was able to block this inhibitory effect of riLl[3 (IRAP + rIL-l[3-treated islets; 41 + 7 ng insulin/10 islets x 60 min, n = 4,p > 0.2 vs controls andp < 0.05 vs rIL-1[3-treated islets). IRAP by itself did not interfere with the insulin release of the mouse islets (IRAP-treated islets; 45 _+ 3 ng insulin/10 islets • 60 min). Thus, mouse islet cells seem to possess similar IL-1 receptors as the rat islet cells.
The islets of Langerhans contain an heterogeneous cell population. Even considering that the prolonged preculture (5-7 days) before exposure to rIL-l[3 possibly eliminated most of the non-endocrine cells in the islets, it cannot be excluded that rIL-l[3 acted through generation of a secondary signal from non-Beta cells. If this is the case, the protective action of IRAP could be due to blocking an IL-1 receptor on non-Beta-cells. To address this issue, we tested the effects of 48 h exposure to rIL-l[3 (5 ng/ml) and IRAP (5000 ng/ml) on an insulinoma cell line, RINm5E As previously observed [3] , rIL-l[3 induced a reduction of cell replication over a period of 48 h in culture. Hence, the It has been suggested that naturally produced IRAP can be an IL-1 inhibitor, with the role of regulating and limiting in vivo certain IL-1 functions [7] . If this hypothesis is confirmed, it can explain why Beta-cell damage is not a common sequel of situations in which high serum levels of IL-1 are observed (e.g. septicaemia). Furthermore, two recent reports suggest that in vivo blocking of the IL-1 receptor can decrease the systemic inflammatory response to turpentine in mice [8] and protect against immune complex colitis in rabbits [9] . In this context, it is conceivable that IRAP may be a useful therapeutic agent for the early treatment of insulin-dependent diabetes. However, extensive studies on the effects of IRAP on the evolution of insulin-dependent diabetes in rodents must be performed to test the validity of this hypothesis.
